ALKYLAMINE
Micro CapAlkyl Amines Chemicals Limited
Industrials
Alkyl Amines Chemicals Limited manufactures aliphatic amines and specialty chemicals. The company serves diverse end-user industries including pharmaceuticals, agrochemicals, rubber chemicals, water treatment, and electronic chemicals.
One read, four checks
75+ is strong, 60-74 is usable, 45-59 is mixed, and below 45 needs caution. These are research lenses, not buy/sell instructions.
Investable fundamentals, management trust is supportive, price trend is neutral, and recent execution is consistent.
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
low confidence · 0/0 claims checked
Timing lens: price trend and sector relative strength.
Rolling lens: recent quarterly delivery, not the latest single-result score.
Quarter ended 31 Mar 2026
Bad · 0/100PAT -2% YoY · margin compression · Rev +0% YoY · +9% QoQ
| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹387 Cr | +0.3% | +9.3% |
| EBITDA | ₹71 Cr | +4.4% | +6.0% |
| Operating margin | 18.0% | +0 bps | -100 bps |
| PAT | ₹45 Cr | -2.2% | +7.1% |
| PAT margin | 11.6% | -29 bps | -23 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Where growth can come from, and what can break the case
FY26 top line and bottom line remained flat YoY, with Q4 operations facing challenges due to ammonia sourcing disruptions and raw material price volatility.
FY26 performance was flat, impacted by raw material price volatility and increased competition in methylamines. While management expects margin improvement and volume growth, geopolitical uncertainty and overcapacity in a key product segment pose ongoing challenges.
Sales by End-User Industry
Latest issuer-disclosed distribution across 3 reported categories.
Acetonitrile Demand
We are optimistic that in acetonitrile and peptides, there will be some volume growth.
Peptides Segment
There is still a lot of optimism, a lot of talk about growth, but most of it has to still materialize. It's a great addition to the acetonitrile market.
New Product Development
Products which we are already launching, which will probably come into the market in July, are also from our R&D pipeline.
Kurkumbh Project Commissioning
The project will probably be commissioned at the beginning of the next quarter (Q1 FY27). Mechanical completion is going to be completed somewhere at the end of June.
Existing Product Capacity
We have enough capacity for the next few years without having to invest anything more in the existing product capacities.
Reduced Chinese Aggression
We have seen over the last quarter, a reduction in the aggressiveness of the Chinese, and we hope it will continue.
Antidumping Duty on Acetonitrile
We got the benefit of that antidumping duty towards the end of the year, leading to some improvement in our pricing.
Pharma Industry Demand
The pharma has always been a little optimistic. They were exempt from most of these tariffs.
Raw Material Price Volatility
The immediate impact of the war has been that the prices have risen both of our raw materials.
Ammonia Sourcing Disruption
We had a few challenges in March in operations, but we have, by and large, overcome it.
Methylamine Overcapacity
There is an overhang of capacity because a new player has come in. Aarti has also commissioned their plant.
Geopolitical Uncertainty
The future remains a little uncertain as long as the war continues, which we hope will get resolved soon.
Demand Destruction from High Prices
It is a bit difficult to predict whether this will have an impact on the demand. Currently, we haven't seen it because it's too early.
Competition in Methylamines
Now that we have 4 players in methylamine in the country, we expect there will be competition.
Monsoon Impact on Agro Demand
There is a little bit of concern that agro could be affected, not pharma as much as agro because they expect this monsoon also with the El Nino.
What management said, and what results must prove
Issuer guidance and extracted claims are tracked against later reported outcomes. Treat these as management statements, not IndiaPulse forecasts.
FY26 results are compared YoY for overall annual performance. Q4 commentary highlights recent impacts of geopolitical events on raw material sourcing and prices, making QoQ relevant for sequential momentum and margin shifts.
FY26 Volume Growth
Volume and value have been basically flat, plus-minus 1% either way; prices dropped 1% and volume probably dropped 1%.
Capacity Utilization
On an average, we must be having between 60% and 85% capacity utilization across our plants.
Ammonia Raw Material Price
Ammonia was in the region of about INR50 a kg and now we are over INR100 a kg.
Acetonitrile Product Price
Today, I think we are at about INR250 per kg. Last year's average, it came down to something like INR140, INR150.
Cautious Optimism
We look forward to what I would say, cautious optimism. I think we will do better than what we have over the last 3 years.
Expected Volume Growth
We expect that the next year will be like a normal year, which is about 5% to 10% growth rate.
FY27 Capex Plan
There is no major business project, just a bit of what is left over from the current new product plant at Dahej and a few engineering projects, around INR80 crores to INR90 crores.
R&D Product Disclosure Policy
We do not talk about our R&D products till the product is in the market. We announce it to the market after the plant is commissioned.
Numbers and claims to verify in the next filings
| Checkpoint | Current evidence | What to verify next |
|---|---|---|
| Kurkumbh Project Commissioning | Mechanical completion by end of June, commissioning in Q1 FY27. | Timely commissioning and ramp-up of the new project to contribute to revenue. |
| Raw Material Price Stabilization | Ammonia prices over INR100/kg, other RMs also rising. | Stabilization of supply chains and raw material prices, expected in 3-6 months, to reduce volatility. |
| Methylamine Capacity Utilization | Overcapacity due to new player (Aarti) commissioning plant. | Signs of market absorption of new methylamine capacity and impact on competitive intensity and margins. |
| Chinese Import Aggressiveness | Reduction in aggressiveness observed in the last quarter. | Continued reduction in Chinese imports and pricing aggression to support domestic margins. |
Verification checkpoints are IndiaPulse research interpretation, not investment advice.
Trend score and candlestick chart
56NeutralSMA20 +20.7% / mo · near 52W high
Technical chart
ALKYLAMINEdaily · 3Y+5.1%Technical trend read
Bullish setupTrend is constructive — long-term trend unclear. RSI 63.
- SMA20 rising (~11.3% over last month) — short-term momentum positive.
- RSI(14) at 63 — rising, no extreme reading.
- MACD above signal, histogram expanding — bullish momentum building.
- Within 3% of 52-week high — testing resistance.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Valuation, score drivers, trust methodology, financials, and peers
Use these sections after reviewing the decision summary, latest result, thesis, management accountability, and technical timing above.
Fundamental score breakdown
UNDERVALUEDWhy this score?
Top U-Score contributors and drags from the latest stored fundamentals.
Positive drivers
- Piotroski is strong at 8/9.
- Quality contributes 20/20 to the score.
- Growth contributes 21/25 to the score.
Main drags
- Fair-value margin of safety is negative at -4.2%.
- Valuation is weaker at 0/30; verify the latest quarterly trend.
- Balance sheet is weaker at 10/15; verify the latest quarterly trend.
Cyclical valuation: normalized earnings, not just trailing PE
Cyclical companies can look cheapest near peak profits, so IndiaPulse flags value-trap risk separately.
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Score history
12 stored score snapshots. Latest stored move: -2 points.
Factor attribution
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
High Trust: Claim history is still being built. It ranks around the 99th percentile of the scored universe and 99th percentile within Industrials. No major sub-score weakness stands out.
High Trust Lite: Promoter holding is 72.1%.
Management behaviour ranks as unusually reliable. Still verify valuation and cycle risk.
overall median 67 · Industrials: 99th pctile, median 68 · Micro: 98th pctile, median 71
0 documents indexed, but claim history is not strong enough yet.
0 claims extracted · No contradicted claim yet
How to read this Trust Score
High Trust · low confidenceRead Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Trust positives
- ▸Promoter holding is 72.1%.
- ▸Promoter pledge is zero.
- ▸FCF yield is positive at 1.7%.
- ▸8 years of positive FCF.
Trust risks
- ▸No major Trust Lite risk flags.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Intrinsic value
Fundamentals
Valuation
- P/E
- 48.20
- P/B
- 17.04
- EV/EBITDA
- 32.52
- Market Cap
- 9149.00Cr
Profitability
- ROE
- 41.40%
- ROCE
- 41.30%
- ROA
- 25.67%
- Dividend Y
- 0.56%
Growth (CAGR)
- Revenue 5Y
- 16.00%
- EPS 5Y
- 33.00%
- Revenue 3Y
- 26.00%
- EPS 3Y
- 54.00%
Balance Sheet
- Debt/Equity
- 0.16
- Interest Coverage
- 25.70×
- Altman Z
- 9.54
- Book Value
- 105.00
Cash Flow
- FCF Yield
- 1.61%
- FCF Positive Y
- 8/5
- OCF
- 188.00 Cr
- EPS TTM
- 39.47
Shareholding
- Promoter Hold
- 72.05%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 47%
Financial History
Updated 9/6/2026
Revenue
₹ CrNet Profit
₹ CrReturn on Equity
%Peers
Business-comparable peers in Industrials — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.